FDA
-
-
-
-
-
-
-
Psychedelic drug developers rally after Trump orders FDA to expedite reviews
-
-
-
-
-
-
-
GH Research PLC (GHRS) PT Raised to $39 at Canaccord Genuity
-
-
-
-
-
-
-
GH Research soars on planned FDA update on depression drug candidate
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on GH Research PLC (GHRS)
-
-
-
-
-
-
-
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
-
-
-
-
-
-
-
GH Research (GHRS) Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
-
-
-
-
-
-
-
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
-
323,577 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

